CN-121987651-A - Use of typha saponin and/or its active metabolite in preparing medicine for preventing and/or treating hyperlipidemia

Abstract

The invention provides an application of typha neoglycoside and/or an active metabolite thereof in preparing a medicament for preventing and/or treating hyperlipidemia, belonging to the technical field of medicines. The typha novel glycoside and/or the active metabolite thereof and pharmaceutically acceptable salts, hydrates, solvates, enantiomers, stereoisomers and tautomers thereof provided by the invention are applied to the preparation of drugs for preventing and/or treating hyperlipidemia. The typha neoglycoside or the active metabolite thereof provided by the invention can obviously reduce the level of triglyceride, total cholesterol, low-density lipoprotein cholesterol and fasting blood glucose in the blood of the ob/ob hyperlipidemia mice, and obviously improve the fat cell hypertrophy in epididymis white adipose tissue caused by hyperlipidemia. Typha glucoside or active metabolite thereof has great market application prospect as a medicament for reducing blood fat and treating hyperlipidemia.

Inventors

• WANG YAN
• XU HUI
• Zuo Hengtong
• FENG RU

Assignees

• 中国医学科学院药物研究所

Dates

Publication Date

20260508

Application Date

20241104

Claims (10)

1. 1. Use of typha neoglycoside or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, stereoisomer, tautomer thereof in the preparation of a medicament for preventing and/or treating hyperlipidemia.
2. 2. Use of typha angustifolia glycoside active metabolite or pharmaceutically acceptable salts, hydrates, solvates, enantiomers, stereoisomers, tautomers thereof for the preparation of a medicament for the prophylaxis and/or treatment of hyperlipidaemia.
3. 3. The use according to claim 2, wherein said typhonine active metabolites include isorhamnetin and protocatechuic acid.
4. 4. A composition for use in the prevention and/or treatment of hyperlipidemia comprising typha neoglycoside or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, stereoisomer, tautomer and typha neoglycoside active metabolite or at least one of a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, stereoisomer, tautomer thereof.
5. 5. A composition for preventing and/or treating hyperlipidemia according to claim 3 further comprising any one or a combination of at least two pharmaceutically acceptable pharmaceutical excipients.
6. 6. A composition for preventing and/or treating hyperlipidemia according to claim 3 wherein the dosage form of the composition comprises any one of the dosage forms which is pharmaceutically acceptable.
7. 7. Use of typha neoglycoside, typha neoglycoside active metabolite or pharmaceutically acceptable salts, hydrates, solvates, enantiomers, stereoisomers, tautomers thereof according to claim 1 or 2 for the manufacture of a medicament for lowering triglyceride levels.
8. 8. Use of typha neoglycoside, typha neoglycoside active metabolite or pharmaceutically acceptable salts, hydrates, solvates, enantiomers, stereoisomers, tautomers thereof according to claim 1 or 2 for the manufacture of a medicament for reducing total cholesterol levels.
9. 9. Use of typha neoglycoside, typha neoglycoside active metabolite or pharmaceutically acceptable salts, hydrates, solvates, enantiomers, stereoisomers, tautomers thereof according to claim 1 or 2 for the preparation of a medicament for lowering low density lipoprotein cholesterol.
10. 10. Use of typha neoglycoside, typha neoglycoside active metabolite or pharmaceutically acceptable salts, hydrates, solvates, enantiomers, stereoisomers, tautomers thereof according to claim 1 or 2 for the preparation of a medicament for reducing fasting blood glucose levels.

Description

Use of typha saponin and/or its active metabolite in preparing medicine for preventing and/or treating hyperlipidemia Technical Field The invention belongs to the technical field of medicines, and particularly relates to application of typha neoglycoside and/or active metabolites thereof in preparation of medicines for preventing and/or treating hyperlipidemia. Background Hyperlipidemia (HYPERLIPIDEMIA) is a disorder of blood lipid metabolism in the body, resulting in abnormally elevated lipids, such as total cholesterol (Total cholesterol, TC), low-density lipoprotein cholesterol (Low density lipoprotein cholesterol, LDL-C), and triglycerides (TRIGLYCERIDES, TG). With the improvement of the living standard of people and the aggravation of the aging of the global population, the incidence of metabolic diseases such as obesity, diabetes, atherosclerosis, cerebral apoplexy, coronary heart disease, myocardial infarction and the like is rapidly increased, and the chronic diseases are closely related to hyperlipidemia, and the investigation of the blood fat of adults in China shows that the incidence of dyslipidemia is 40.4 percent at present and is increased year by year. Abnormal elevation of cholesterol in blood can cause pathological phenomena such as blood vessel lumen wall blood lipid deposition, blood vessel stenosis occlusion, arteriosclerosis and the like, is an important cause of cardiovascular and cerebrovascular diseases, and hyperlipidemia is also called "chronic disease king". The current blood lipid reducing drugs mainly comprise statins, but have side effects of liver and kidney toxicity, rhabdomyolysis and the like. The traditional Chinese medicine has the advantage of small toxic and side effects, so that the search of a new medicine for treating hyperlipidemia from the traditional Chinese medicine has very necessary significance. Typha neoglycoside (Typhaneoside) is a flavonoid component extracted from pollen of typha plants (e.g., angustifolia She Xiangpu, typha angustifolia. L), originally discovered and named in 1986 by the national academy of medical sciences pharmaceutical research, which is soluble in water for clinical and scientific applications. The compound has the pharmacological effects of improving microcirculation, reducing oxygen consumption of heart and brain tissues, procoagulant, dilating blood vessels, resisting inflammation, reducing blood fat, resisting atherosclerosis and the like, and has good prospect of medicinal application. Studies show that typha neoglycoside can reduce the expression of inflammatory factors of intestinal epithelial cells of mice so as to play an anti-inflammatory role, a novel way is provided for treating colonitis and related diseases, and the typha neoglycoside also has related patents in the aspects of treating hyperuricemia and kidney injury and reducing uric acid. However, no report on typha glycoside for preventing and treating hyperlipidemia is found in the prior art. Disclosure of Invention In view of the above, the present invention aims to provide the application of typha neoglycoside and/or its active metabolite in preparing the medicine for preventing and/or treating hyperlipidemia. The typha neoglycoside or the active metabolite thereof provided by the invention can obviously reduce the level of triglyceride, total cholesterol, low-density lipoprotein cholesterol and fasting blood glucose in the blood of the ob/ob hyperlipidemia mice, and obviously improve the fat cell hypertrophy in epididymis white adipose tissue caused by hyperlipidemia. Typha glucoside or active metabolite thereof has great market application prospect as a medicament for reducing blood fat and treating hyperlipidemia. In order to achieve the above object, the present invention provides the following technical solutions: the invention provides an application of typha neoglycoside or pharmaceutically acceptable salts, hydrates, solvates, enantiomers, stereoisomers and tautomers thereof in preparing medicines for preventing and/or treating hyperlipidemia. The invention also provides application of typha angustifolia glycoside active metabolite or pharmaceutically acceptable salt, hydrate, solvate, enantiomer, stereoisomer and tautomer thereof in preparing medicines for preventing and/or treating hyperlipidemia. Preferably, the typha angustifolia glycoside active metabolites include isorhamnetin and protocatechuic acid. The invention also provides a composition for preventing and/or treating hyperlipidemia, comprising typha neoglycoside or pharmaceutically acceptable salt, hydrate, solvate, enantiomer, stereoisomer, tautomer and typha neoglycoside active metabolite or at least one of pharmaceutically acceptable salt, hydrate, solvate, enantiomer, stereoisomer and tautomer thereof. Preferably, the composition further comprises any one or a combination of at least two pharmaceutically acceptable pharmaceutical excipients. Preferably, the dosage form of the composition co